News - Desert King

Ramezani-Rad, .P, et al. The saponin monophosphoryl lipid A nanoparticle adjuvant induces dose-dependent HIV vaccine responses in non-human primates.

The use of an appropriate adjuvant is crucial for developing an effective HIV vaccine. This study investigates the efficacy of QS-21-based saponin/monophosphoryl lipid A ...

Zhu, Q., et al. Harnessing phytochemicals: Innovative strategies to enhance cancer immunotherapy.

The article explores the promising role of phytochemicals, particularly saponins like Quil A and its derivative QS-21 from Quillaja saponaria, in enhancing cancer immunot...

Gaspar, E.B., et al. Adjuvant-driven antibody response to use cows as biofactories of anti-SARS-CoV-2 neutralizing antibodies in colostrum.

Bovine colostrum has the potential to serve as a source of neutralizing antibodies for preventing viral infections due to the evolutionary homology between bovine and hum...

Hickey, J., et al. Two recombinant cytomegalovirus antigens formulated with the SPA14 adjuvant system: Impact of temperature, pH and excipients on the stability of each antigen and adjuvant component.

The study evaluated the stability of two recombinant Cytomegalovirus antigens (gB and Pentamer) formulated with the SPA14 adjuvant system, a liposomal formulation contain...

Ye, L., et al. Effects of immune response on different nano-adjuvants combined with H11 antigen of Haemonchus contortus.

The study indicates that nano-adjuvants offer a promising alternative to traditional adjuvants for inducing robust and lasting immune responses, particularly in the conte...

Ma W. et. al.: Enhanced Antitumor Immunity of a Globo H-Based Vaccine Enabled by the Combination Adjuvants of 3D-MPL and QS-21.

The study presents a novel adjuvant-assisted Globo H-based anticancer vaccine platform. The article advocates for the efficacy of a combination QS-21/3D-MPL adjuvant.

Venkatraman, N., et al. Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

Comments from Desert King: The R21/Matrix-M malaria vaccine uses Novavax's proprietary Matrix-M adjuvant technology to help prevent malaria in children. The R21 Ag was de...

Pirahmadi S. et. al.: Selection of combination adjuvants for enhanced immunogenicity of a recombinant CelTOS vaccine against Plasmodium falciparum.

In the current study, the immunogenicity of Plasmodium falciparum cell traversal protein for ookinetes and sporozoites (PfCelTOS) were intended to improve by three differ...